Pre- and Postoperative Use of ZD1839 (Iressa) in Recurrent Glioblastoma, Including Translational Research
PHASE2CompletedINTERVENTIONAL
Enrollment
22
Participants
Timeline
Start Date
July 31, 2005
Study Completion Date
May 31, 2007
Conditions
Recurrent Glioblastoma
Interventions
DRUG
Gefitnib
Trial Locations (1)
8091
University Hospital Zürich, Zurich
All Listed Sponsors
lead
University of Zurich
OTHER
NCT00250887 - Pre- and Postoperative Use of ZD1839 (Iressa) in Recurrent Glioblastoma, Including Translational Research | Biotech Hunter | Biotech Hunter